<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" id="cas13513-fig-0001" orientation="portrait" position="float">
 <label>Figure 1</label>
 <caption>
  <p>Mean serum concentrations of E7777 on day 1, cycle 1 of a phase I study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma. Patients were allocated to three treatment regimens: 6 μg/kg/day cohort (n = 3), 9 μg/kg/day cohort (n = 5), and 12 μg/kg/day cohort (n = 2). Error bars indicate 
   <styled-content style="fixed-case">SD</styled-content>
  </p>
 </caption>
 <graphic id="nlm-graphic-3" xlink:href="CAS-109-794-g001" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
